Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arrigo Schieppati

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|March 2, 2013
Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trialsYizhi Chen, Arrigo Schieppati, Guangyan Cai, et al.
The Cochrane Database of Systematic Reviews|October 17, 2014
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndromeYizhi Chen, Arrigo Schieppati, Xiangmei Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 1, 2017
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic SyndromeLuca Perico, Mario Mandalà, Arrigo Schieppati, et al.
Pediatric Nephrology (Berlin, Germany)|September 1, 2014
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapyRosanna Coppo, Licia Peruzzi, Alessandro Amore, et al.
Blood Transfusion = Trasfusione Del Sangue|June 13, 2014
The social burden and quality of life of patients with haemophilia in ItalyYllka Kodra, Marianna Cavazza, Arrigo Schieppati, et al.
Lancet (London, England)|March 11, 2015
Rare diseases and effective treatments: are we delivering?Lucio Luzzatto, Carla E M Hollak, Timothy M Cox, et al.
Lancet (London, England)|July 25, 2018
Outrageous prices of orphan drugs: a call for collaborationLucio Luzzatto, Hanna I Hyry, Arrigo Schieppati, et al.
Lancet (London, England)|June 4, 2013
Kidney failure: aims for the next 10 years and barriers to successGiuseppe Remuzzi, Ariela Benigni, Fredric O Finkelstein, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 4, 2016
Social/economic costs and health-related quality of life in patients with scleroderma in EuropeJulio López-Bastida, Renata Linertová, Juan Oliva-Moreno, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 25, 2016
Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in EuropeAris Angelis, Panos Kanavos, Julio López-Bastida, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Clinical Journal of the American Society of Nephrology : CJASN|March 2, 2013
Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trialsYizhi Chen, Arrigo Schieppati, Guangyan Cai, et al.
The Cochrane Database of Systematic Reviews|October 17, 2014
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndromeYizhi Chen, Arrigo Schieppati, Xiangmei Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 1, 2017
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic SyndromeLuca Perico, Mario Mandalà, Arrigo Schieppati, et al.
Pediatric Nephrology (Berlin, Germany)|September 1, 2014
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapyRosanna Coppo, Licia Peruzzi, Alessandro Amore, et al.
Blood Transfusion = Trasfusione Del Sangue|June 13, 2014
The social burden and quality of life of patients with haemophilia in ItalyYllka Kodra, Marianna Cavazza, Arrigo Schieppati, et al.
Lancet (London, England)|March 11, 2015
Rare diseases and effective treatments: are we delivering?Lucio Luzzatto, Carla E M Hollak, Timothy M Cox, et al.
Lancet (London, England)|July 25, 2018
Outrageous prices of orphan drugs: a call for collaborationLucio Luzzatto, Hanna I Hyry, Arrigo Schieppati, et al.
Lancet (London, England)|June 4, 2013
Kidney failure: aims for the next 10 years and barriers to successGiuseppe Remuzzi, Ariela Benigni, Fredric O Finkelstein, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 4, 2016
Social/economic costs and health-related quality of life in patients with scleroderma in EuropeJulio López-Bastida, Renata Linertová, Juan Oliva-Moreno, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|April 25, 2016
Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in EuropeAris Angelis, Panos Kanavos, Julio López-Bastida, et al.
Pageof 6